Last reviewed · How we verify
fenofibric acid 105 mg
At a glance
| Generic name | fenofibric acid 105 mg |
|---|---|
| Also known as | FIBRICOR |
| Sponsor | Mutual Pharmaceutical Company, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz (PHASE1)
- A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz (PHASE1)
- Fasted Pharmacokinetic and Bioequivalency Study of Fenofibric Acid (PHASE1)
- Bioequivalence Study of Fenofibric Acid Versus Tricor® (Fenofibrate) (PHASE1)
- Fed Bioequivalence Study of Fenofibric Acid Versus TriCor® (Fenofibrate) (PHASE1)
- Four Arm Food Effect Study of Fenofibric Acid Tablets (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fenofibric acid 105 mg CI brief — competitive landscape report
- fenofibric acid 105 mg updates RSS · CI watch RSS
- Mutual Pharmaceutical Company, Inc. portfolio CI